Zusammenfassung
Das DRESS („Drug Reaction with Eosinophilia and Systemic Symptoms“; syn.: Hypersensitivitätssyndrom) ist eine schwere, potenziell lebensbedrohliche Arzneimittelreaktion. Die Mortalität liegt bei 10 %; die Inzidenz ist weltweit zunehmend. Die häufigsten Auslöser sind aromatische Antikonvulsiva (Carbamazepin, Lamotrigin, Phenobarbital) und zunehmend moderne antiretrovirale Medikamente. Die Pathogenese ist nicht vollends geklärt, wahrscheinlich multifaktoriell mit Zusammentreffen von Immunreaktion, ethnischer Prädisposition, genetisch determiniertem Enzymmangel und Reaktivierung von Herpesviren (HHV-6, HHV-7, Epstein-Barr-Virus, Zytomegalievirus). Infolge Haut- und Multiorganbeteiligung ist das klinische Bild variabel, sodass kein eindeutiger klinischer, histologischer oder laborchemischer Phänotyp charakterisiert werden kann. Dies wird durch eine lange Latenz zwischen Beginn der Medikamenteneinnahme und Beginn des DRESS bzw. sukzessives Auftreten von Haut- und Organbeteiligung erschwert. Auch wenn oder gerade weil das DRESS eine diagnostische Herausforderung darstellt, ist eine genaue Kenntnis des Krankheitsbildes wichtig, um frühzeitig therapeutische Maßnahmen einleiten zu können.
Abstract
DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms), also known as hypersensitivity syndrome (HSS), is a severe and potentially life-threatening drug reaction. The worldwide rate of mortality is about 10 %, its incidence is increasing. Drugs that most frequently induce DRESS are aromatic anticonvulsive drugs (carbamazepine, lamotrigine, phenobarbital), and more recently new retroviral therapies. The pathogenesis of DRESS is not yet fully understood, but is certainly multifactorial involving a combination of immune reactions, ethnic predisposition, genetically determined enzyme deficiencies and reactivation of herpes viruses (HHV-6, HHV-7, EBV, CMV). Because of the involvement of the skin and internal organs, the clinical picture can be very variable. No specific clinical, histologic or laboratory parameter is available, so the diagnosis has to rely on the clinical appearance. The long latency period between start of drug intake and the initial manifestation of DRESS and the successive onset of skin and organ involvement complicates the early diagnosis. Although or even because DRESS represents a diagnostic challenge, detailed knowledge about this disease is of utmost importance to enable early therapeutic actions.
Literatur
An J, Lee JH, Lee H et al (2012) Drug rash with eosinophilia and systemic symptoms syndrome following cholestatic hepatitis A: a case report. Korean J Hepatol 18:84–88
Bocquet H, Bagot M, Roujeau JC (1996) Drug induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms). Semin Cutan Med Surg 15:250–257
Halink DA, Marijnissen RM et al (2011) Drug reaction with eosinophilia and systemic symptoms induced by carbamazepine: DRESSed to kill. Gen Hosp Psychiatry 33:412
Shiohara T, Inaoka M, Kano Y (2006) Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses. Allergol Int 55:1–8
Shiohara T, Kano Y, Takahashi R et al (2012) Drug-induced hypersensitivity syndrome: recent advances in the diagnosis, pathogenesis and management. Chem Immunol Allergy 97:122–138
Giri PP, Roy S, Bhattyacharya S et al (2011) Dress syndrome with sepsis, acute respiratory distress syndrome and pneumomediastinum. Indian J Dermatol 56:763–765
Bauer KA, Brimhall AK, Chang TT (2011) Drug reaction with eosinophilia and systemic symptoms (DRESS) associated with azithromycin in acute Epstein-Barr virus infection. Pediatr Dermatol 28:741–743
Shiohara T, Kano Y (2007) A complex interaction between drug allergy and viral infection. Clin Rev Allergy Immunol 33:124–133
Kardaun SH, Sidoroff A, Valeyrie-Allanore L et al (2007) Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: Does a DRESS syndrome really exist? Br J Dermatol 156:609–611
Walsh S, Diaz-Cano S, Higgins E et al (2013) Drug reaction with eosinophilia and systemic symptoms: Is cutaneous phenotype a prognostic marker for outcome? A review of clinicopathological features of 27 cases. Br J Dermatol 168:391–401
Gómez-Zorrilla S, Ferraz AV, Pedrós C et al (2012) Levetiracetam-induced drug reaction with eosinophilia and systemic symptoms syndrome. Ann Pharmacother 46:e20
Mockenhaupt M (2009) Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy. J Dtsch Dermatol Ges 7:142–160
Criado PR, Criado RF, Avancini Jde M et al (2012) Drug reaction with eosinophilia and systemic symptoms (DRESS)/drug-induced hypersensitivity syndrome (DIHS): a review of current concepts. An Bras Dermatol 87:435–449
Kong Q, Sang H, Zhang M et al (2012) Rhabdomyolysis associated with roxithromycin hypersensitivity syndrome. Indian J Dermatol Venereol Leprol 78:197–199
Müller PA, Amann K, Bröcker EB et al (2012) Maculo-papular exanthem with acute renal failure. Drug-induced hypersensitivity syndrome. Hautarzt 63:223–255
Ang CC, Wang YS, Yoosuff EL et al (2010) Retrospective analysis of drug-induced hypersensitivity syndrome: a study of 27 patients. J Am Acad Dermatol 63:219–227
Lehmann P, Hartung W, Fleck M (2013) Rhabdomyolysis and creatine kinase elevation. Z Rheumatol 72:236–241
Ogawa K, Morito H, Hasegawa A et al (2013) Identification of thymus and activation-regulated chemokine (TARC/CCL17) as a potential marker for early indication of disease and prediction of disease activity in drug-induced hypersensitivity syndrome (DIHS)/drug rash with eosinophilia and systemic symptoms (DRESS). J Dermatol Sci 69(1):38–43
Ganeva M, Gancheva T, Lazarova R et al (2008) Carbamazepine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: report of four cases and brief review. Int J Dermatol 47:853–860
Cacoub P, Musette P, Descamps V et al (2011) The DRESS syndrome: a literature review. Am J Med 124:588–597
Bensaid B, Rozieres A, Nosbaum A et al (2012) Amikacin-induced drug reaction with eosinophilia and systemic symptoms syndrome: delayed skin test and ELISPOT assay results allow the identification of the culprit drug. J Allergy Clin Immunol 130:1413–1414
Kang SY, Kim JY, Kim MY et al (2012) Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms syndrome induced by cilostazol and carbamazepine. J Dermatol 39:723–724
Loulergue P, Mir O (2012) Raltegravir-induced DRESS syndrome. Scand J Infect Dis 44:802–803
Roujeau JC, Mockenhaupt M, Tahan SR et al (2013) Telaprevir-related dermatitis. JAMA Dermatol 149:152–158
Bayonne Kombo ES, Gathse A (2013) Tenofovir hypersensitivity to tenofovir (DRESS) syndrome in a female patient infected by HIV. Med Mal Infect 43:134–135
Rawlins MD, Thompson JW (1977) Pathogenesis of adverse drug reactions. In: Davies DM (Hrsg) Textbook of adverse drug reactions. Oxford University Press, Oxford, S 10
Hausmann O, Schnyder B, Pichler WJ (2012) Etiology and pathogenesis of adverse drug reactions. Chem Immunol Allergy 97:32–46
Takahashi R, Kano Y, Yamazaki Y et al (2009) Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome. J Immunol 182:8071–8079
Camous X, Calbo S, Picard D et al (2012) Drug reaction with eosinophilia and systemic symptoms: an update on pathogenesis. Curr Opin Immunol 24:730–735
Bohan KH, Mansuri TF, Wilson NM (2007) Anticonvulsant hypersensitivity syndrome: implications for pharmaceutical care. Pharmacotherapy 27:1425–1439
Tohyama M, Hashimoto K, Yasukawa M et al (2007) Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome. Br J Dermatol 157:934–940
Barbaud A, Waton J, Herbeth B et al (2013) Comparison of cytokine gene polymorphism in drug-induced maculopapular eruption, urticaria and drug reaction with eosinophilia and systemic symptoms (DRESS). J Eur Acad Dermatol Venereol [Epub ahead of print]
Ostrov DA, Grant BJ, Pompeu YA et al (2012) Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci U S A 109:9959–9964
Norcross MA, Luo S, Lu L et al (2012) Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity. AIDS 26:21–29
Saag M, Balu R, Phillips E et al (2008) Study of Hypersensitivity to Abacavir and Pharmacogenetic Evaluation Study Team. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis 46:1111–1118
Pirmohamed M (2012) Genetics and the potential for predictive tests in adverse drug reactions. Chem Immunol Allergy 97:18–31
Profaizer T, Eckels D (2012) HLA alleles and drug hypersensitivity reactions. Int J Immunogenet 39:99–105
http://www.pei.de/cln_236/nn_154420/SharedDocs/Downloads/vigilanz/bulletin-zur-arzneimittelsicherheit/2012/2-2012,templateId=raw, property=publicationFile.pdf/2-2012.pdf
Neuman MG, Cohen L, Nanau RM et al (2012) Genetic and immune predictors for hypersensitivity syndrome to antiepileptic drugs. Transl Res 159:397–406
Chiu ML, Hu M, Ng MH et al (2012) Association between HLA-B*58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong. Br J Dermatol 167:44–49
Phillips EJ, Chung WH, Mockenhaupt M et al (2011) Drug hypersensitivity: pharmacogenetics and clinical syndromes. J Allergy Clin Immunol 127:60–66
(o A) (2008) „Quality assurance in the lymphocyte transformation test“ – addendum to the LTT publication „Methods and quality assurance in environmental medicine“ by the RKI Committee. „Methods and quality assurance in environmental medicine“ report by the committee. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 51:1070–1076
Descamps V, Ben-Saïd B, Sassolas B et al (2010) Management of drug reaction with eosinophilia and systemic symptoms (DRESS). Ann Dermatol Venereol 137:703–708
Moling O, Tappeiner L, Piccin A et al (2012) Treatment of DIHS/DRESS syndrome with combined N-acetylcysteine, prednisone and valganciclovir – a hypothesis. Med Sci Monit 18:57–62
Finanzierung
Der Beitrag wurde bei dem Derma Update 2012 präsentiert.
Interessenkonflikt
S. Ständer, D. Metze, T. Luger und T. Schwarz geben an, dass kein Interessenkonflikt besteht. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ständer, S., Metze, D., Luger, T. et al. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). Hautarzt 64, 611–624 (2013). https://doi.org/10.1007/s00105-013-2615-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00105-013-2615-0